October 6, 2025 at 11:52 AM
This week (and tonight on #NephJC) we are discussing the REGENCY trial on #obinutuzumab in SLE specifically #lupus nephritis
summary from
@sayalibthakare.bsky.social
@dramiliflores.bsky.social & @nephroseeker.medsky.social
www.nephjc.com/news/regency...
#lupuschat #NephSky #RheumSky
summary from
@sayalibthakare.bsky.social
@dramiliflores.bsky.social & @nephroseeker.medsky.social
www.nephjc.com/news/regency...
#lupuschat #NephSky #RheumSky
Obinutuzumab in Lupus Nephritis — NephJC
This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not ...
www.nephjc.com
March 11, 2025 at 12:56 PM
This week (and tonight on #NephJC) we are discussing the REGENCY trial on #obinutuzumab in SLE specifically #lupus nephritis
summary from
@sayalibthakare.bsky.social
@dramiliflores.bsky.social & @nephroseeker.medsky.social
www.nephjc.com/news/regency...
#lupuschat #NephSky #RheumSky
summary from
@sayalibthakare.bsky.social
@dramiliflores.bsky.social & @nephroseeker.medsky.social
www.nephjc.com/news/regency...
#lupuschat #NephSky #RheumSky
Our latest video in partnership with @glaucomflecken.bsky.social summarizes the ALLEGORY trial that evaluated the efficacy and safety of obinutuzumab when added to standard therapy in adults with active systemic lupus erythematosus. Read the full study for free: https://nej.md/DrG49
#rheumatology
#rheumatology
September 22, 2026 at 4:01 PM
Our latest video in partnership with @glaucomflecken.bsky.social summarizes the ALLEGORY trial that evaluated the efficacy and safety of obinutuzumab when added to standard therapy in adults with active systemic lupus erythematosus. Read the full study for free: https://nej.md/DrG49
#rheumatology
#rheumatology
For patients with lupus nephritis, a recent phase 2 trial showed that the addition of obinutuzumab to standard therapy was associated with a significantly better renal response than placebo. Findings of the REGENCY phase 3 trial are summarized in a new Quick Take video. youtu.be/cqu42EDvPq8
#MedSky
#MedSky
Obinutuzumab in Lupus Nephritis (REGENCY trial) | NEJM
YouTube video by NEJM Group
youtu.be
April 18, 2025 at 7:33 PM
For patients with lupus nephritis, a recent phase 2 trial showed that the addition of obinutuzumab to standard therapy was associated with a significantly better renal response than placebo. Findings of the REGENCY phase 3 trial are summarized in a new Quick Take video. youtu.be/cqu42EDvPq8
#MedSky
#MedSky
In the REGENCY trial, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, plus standard therapy provided significantly better renal responses than standard therapy alone in patients with lupus nephritis. Full trial results: nej.md/3Eq6gxV
#ISNWCN | @theisn.org
#ISNWCN | @theisn.org
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis | NEJM
Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly
better renal responses than placebo in a phase 2 trial involving patients with lupus
nephritis receiving stan...
nej.md
February 7, 2025 at 2:15 PM
In the REGENCY trial, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, plus standard therapy provided significantly better renal responses than standard therapy alone in patients with lupus nephritis. Full trial results: nej.md/3Eq6gxV
#ISNWCN | @theisn.org
#ISNWCN | @theisn.org
Obinutuzumab in Active Lupus Nephritis is a nice example of drug repurposing - Vivek Subbiah
@viveksubbiah.bsky.social
oncodaily.com/science/2780...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Lupus #Nephritis #Obinutuzumab
@viveksubbiah.bsky.social
oncodaily.com/science/2780...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Lupus #Nephritis #Obinutuzumab
Vivek Subbiah: Obinutuzumab in Active Lupus Nephritis is a nice example of drug repurposing - OncoDaily
Vivek Subbiah: Obinutuzumab in Active Lupus Nephritis is a nice example of drug repurposing / Active Lupus Nephritis, cancer, CLL, drug repurposing,
oncodaily.com
April 20, 2025 at 6:46 PM
Obinutuzumab in Active Lupus Nephritis is a nice example of drug repurposing - Vivek Subbiah
@viveksubbiah.bsky.social
oncodaily.com/science/2780...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Lupus #Nephritis #Obinutuzumab
@viveksubbiah.bsky.social
oncodaily.com/science/2780...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Lupus #Nephritis #Obinutuzumab
In the latest video in our partnership with @glaucomflecken.bsky.social, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free: nej.md/DrG20
July 1, 2025 at 7:04 PM
In the latest video in our partnership with @glaucomflecken.bsky.social, the REGENCY trial investigating the efficacy and safety of obinutuzumab when added to standard therapy in patients with active proliferative lupus nephritis is explained. Access the article for free: nej.md/DrG20
REGENCY: Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis ca. 2025
#Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/39927615/
👉🏼 www.asn-online.org/publications...
#Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/39927615/
👉🏼 www.asn-online.org/publications...
March 6, 2025 at 12:52 AM
REGENCY: Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis ca. 2025
#Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/39927615/
👉🏼 www.asn-online.org/publications...
#Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/39927615/
👉🏼 www.asn-online.org/publications...
A study examined the efficacy and safety of obinutuzumab to treat patients with focal segmental glomerulosclerosis who were treatment-resistant or dependent on immunosuppressive therapy. #nephrology #nephsky #KidneyWk #FSGS #kidneydisease
Obinutuzumab Efficacy, Safety for FSGS Treatment | Docwire News
Obinutuzumab reduced proteinuria in patients with focal segmental glomerulosclerosis (FSGS) who were treatment-resistant or dependent on immunosuppressive therapy.
buff.ly
January 17, 2025 at 8:46 PM
A study examined the efficacy and safety of obinutuzumab to treat patients with focal segmental glomerulosclerosis who were treatment-resistant or dependent on immunosuppressive therapy. #nephrology #nephsky #KidneyWk #FSGS #kidneydisease
Simulpub number 6 at #ERA26
Obi beats tacrolimus in membranous nephropathy
www.nejm.org/doi/full/10.... in NEJM
No surprise after MENTOR
Obi beats tacrolimus in membranous nephropathy
www.nejm.org/doi/full/10.... in NEJM
No surprise after MENTOR
Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy | NEJM
Studies of obinutuzumab, a type II anti-CD20 antibody, have shown efficacy in the treatment of hematologic cancers and autoimmune diseases. An evaluation of the efficacy and safety of obinutuzumab ...
www.nejm.org
June 5, 2026 at 11:47 AM
Simulpub number 6 at #ERA26
Obi beats tacrolimus in membranous nephropathy
www.nejm.org/doi/full/10.... in NEJM
No surprise after MENTOR
Obi beats tacrolimus in membranous nephropathy
www.nejm.org/doi/full/10.... in NEJM
No surprise after MENTOR
Obinutuzumab works in membranous!
Genentech is shooting fish in a barrel. Every disease that responds to Ritux is going to be in their sights.
www.nasdaq.com/articles/gen...
Genentech is shooting fish in a barrel. Every disease that responds to Ritux is going to be in their sights.
www.nasdaq.com/articles/gen...
www.nasdaq.com
February 18, 2026 at 7:18 PM
Obinutuzumab works in membranous!
Genentech is shooting fish in a barrel. Every disease that responds to Ritux is going to be in their sights.
www.nasdaq.com/articles/gen...
Genentech is shooting fish in a barrel. Every disease that responds to Ritux is going to be in their sights.
www.nasdaq.com/articles/gen...
La vue du "condo" au CCJ de HMR aujourd'hui. #Cycle1Traitement4 #Obinutuzumab
October 10, 2025 at 11:31 AM
La vue du "condo" au CCJ de HMR aujourd'hui. #Cycle1Traitement4 #Obinutuzumab
BREAKING NEWS: The FDA has approved Gazyva® (obinutuzumab) for the treatment of adults with #lupus nephritis. Gazyva is the fourth therapy for lupus to receive regulatory approval since 2011.
Read the announcement: buff.ly/81tYgo7
Read the announcement: buff.ly/81tYgo7
October 20, 2025 at 1:02 PM
BREAKING NEWS: The FDA has approved Gazyva® (obinutuzumab) for the treatment of adults with #lupus nephritis. Gazyva is the fourth therapy for lupus to receive regulatory approval since 2011.
Read the announcement: buff.ly/81tYgo7
Read the announcement: buff.ly/81tYgo7
Tonite at 9pm, only on #Blusky, we discuss the new kid on the block for lupus nephritis! Join us for nephrology education as we close in on #WorldKidneyDay #NephSky
Obinutuzumab, a super B-Cell destroyer 💥
www.nephjc.com/news/regency...
Obinutuzumab, a super B-Cell destroyer 💥
www.nephjc.com/news/regency...
Obinutuzumab in Lupus Nephritis — NephJC
This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not ...
www.nephjc.com
March 11, 2025 at 11:45 AM
Tonite at 9pm, only on #Blusky, we discuss the new kid on the block for lupus nephritis! Join us for nephrology education as we close in on #WorldKidneyDay #NephSky
Obinutuzumab, a super B-Cell destroyer 💥
www.nephjc.com/news/regency...
Obinutuzumab, a super B-Cell destroyer 💥
www.nephjc.com/news/regency...
www.nature.com/articles/s41...
Interest now in potent anti-CD20 approaches across lupus and other settings.....
Interest now in potent anti-CD20 approaches across lupus and other settings.....
Positive results for obinutuzumab in SLE phase III trial - Nature Reviews Rheumatology
In the placebo-controlled phase III ALLEGORY trial, treatment with obinutuzumab reduced disease activity in adults with systemic lupus erythematosus over 52 weeks.
www.nature.com
April 28, 2026 at 7:04 AM
www.nature.com/articles/s41...
Interest now in potent anti-CD20 approaches across lupus and other settings.....
Interest now in potent anti-CD20 approaches across lupus and other settings.....
T2e: With obinutuzumab there was a greater reduction in protein-to-creatinine ratio (adjusted difference 13.7%) #NephJC
Proteinuric response (UPCR <0.8 g per gram) without intercurrent events was significantly higher in the obinutuzumab arm (55.5% vs 41.9%)
Proteinuric response (UPCR <0.8 g per gram) without intercurrent events was significantly higher in the obinutuzumab arm (55.5% vs 41.9%)
March 12, 2025 at 1:33 AM
T2e: With obinutuzumab there was a greater reduction in protein-to-creatinine ratio (adjusted difference 13.7%) #NephJC
Proteinuric response (UPCR <0.8 g per gram) without intercurrent events was significantly higher in the obinutuzumab arm (55.5% vs 41.9%)
Proteinuric response (UPCR <0.8 g per gram) without intercurrent events was significantly higher in the obinutuzumab arm (55.5% vs 41.9%)
" #Obinutuzumab ( #Gazyva ) appears set to add systemic #lupus erythematosus ( #SLE ) to its list of approved indications, as results from a phase III trial showed it was significantly more effective than placebo, with no new safety concerns.": buff.ly/WWFikk5
via @medpagetoday.com
#BCell #MedSky
via @medpagetoday.com
#BCell #MedSky
Another B-Cell Drug for Lupus Hits the Mark
Phase III results put obinutuzumab in line for approval
buff.ly
March 7, 2026 at 9:30 AM
" #Obinutuzumab ( #Gazyva ) appears set to add systemic #lupus erythematosus ( #SLE ) to its list of approved indications, as results from a phase III trial showed it was significantly more effective than placebo, with no new safety concerns.": buff.ly/WWFikk5
via @medpagetoday.com
#BCell #MedSky
via @medpagetoday.com
#BCell #MedSky
INShore Phase 3 trial: Obinutuzumab vs MMF in childhood-onset FRNS/SDNS to maintain remission
85 patients / 9 countries
Type II anti-CD20 therapy → ⬇️ B-cell depletion
Primary endpoint met: sustained remission at 52 wks significantly ⬆️ w/obinutuzumab
#ISNWCN
@ISNKidneycare
85 patients / 9 countries
Type II anti-CD20 therapy → ⬇️ B-cell depletion
Primary endpoint met: sustained remission at 52 wks significantly ⬆️ w/obinutuzumab
#ISNWCN
@ISNKidneycare
March 28, 2026 at 8:01 AM
INShore Phase 3 trial: Obinutuzumab vs MMF in childhood-onset FRNS/SDNS to maintain remission
85 patients / 9 countries
Type II anti-CD20 therapy → ⬇️ B-cell depletion
Primary endpoint met: sustained remission at 52 wks significantly ⬆️ w/obinutuzumab
#ISNWCN
@ISNKidneycare
85 patients / 9 countries
Type II anti-CD20 therapy → ⬇️ B-cell depletion
Primary endpoint met: sustained remission at 52 wks significantly ⬆️ w/obinutuzumab
#ISNWCN
@ISNKidneycare
T0l: #NephJC
Type II anti-CD20 mAbs (e.g., obinutuzumab) induce stronger B-cell cytotoxicity and enhanced phagocytosis, resulting in deeper and more sustained depletion, including in tissue-resident B-cell niches
Type II anti-CD20 mAbs (e.g., obinutuzumab) induce stronger B-cell cytotoxicity and enhanced phagocytosis, resulting in deeper and more sustained depletion, including in tissue-resident B-cell niches
March 12, 2025 at 1:18 AM
T0l: #NephJC
Type II anti-CD20 mAbs (e.g., obinutuzumab) induce stronger B-cell cytotoxicity and enhanced phagocytosis, resulting in deeper and more sustained depletion, including in tissue-resident B-cell niches
Type II anti-CD20 mAbs (e.g., obinutuzumab) induce stronger B-cell cytotoxicity and enhanced phagocytosis, resulting in deeper and more sustained depletion, including in tissue-resident B-cell niches
Simultaneous publication during #ISNWCN in @nejm.org
Results From the REGENCY Trial Assessing Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Presented by Brad Rovin
www.nejm.org/doi/full/10....
Results From the REGENCY Trial Assessing Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Presented by Brad Rovin
www.nejm.org/doi/full/10....
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis | NEJM
Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving stan...
www.nejm.org
February 7, 2025 at 9:15 AM
Simultaneous publication during #ISNWCN in @nejm.org
Results From the REGENCY Trial Assessing Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Presented by Brad Rovin
www.nejm.org/doi/full/10....
Results From the REGENCY Trial Assessing Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Presented by Brad Rovin
www.nejm.org/doi/full/10....
Obinutuzumab as a therapeutic option for SDNS children resistant to rituximab with anti-RTX antibodies
rdcu.be/ePZBl
rdcu.be/ePZBl
November 14, 2025 at 8:58 PM
Obinutuzumab as a therapeutic option for SDNS children resistant to rituximab with anti-RTX antibodies
rdcu.be/ePZBl
rdcu.be/ePZBl
Obinutuzumab, REGENCY, & Updates in Lupus Nephritis, With Brad Rovin, MD pca.st/episode/ef70...
November 9, 2025 at 1:08 AM
Obinutuzumab, REGENCY, & Updates in Lupus Nephritis, With Brad Rovin, MD pca.st/episode/ef70...
"Data suggest that #obinutuzumab depletes disease-causing #Bcells, helping limit further damage to the #kidneys [in #LupusNephritis ] & potentially preventing or delaying progression to end-stage #RenalDisease.": buff.ly/qXHef9H
via ACRheum
#lupus #MedSky #ClinicalTrial #SLE #pharmacology #FDA
via ACRheum
#lupus #MedSky #ClinicalTrial #SLE #pharmacology #FDA
FDA Accepts Application for Obinutuzumab for Treatment of Systemic Lupus Erythematosus - The Rheumatologist
On April 20, the FDA accepted the supplemental Biologics License Application for obinutuzumab for the treatment of systemic lupus erythematosus, based on positive results from the phase 3 ALLEGORY…
buff.ly
June 21, 2026 at 9:30 AM
"Data suggest that #obinutuzumab depletes disease-causing #Bcells, helping limit further damage to the #kidneys [in #LupusNephritis ] & potentially preventing or delaying progression to end-stage #RenalDisease.": buff.ly/qXHef9H
via ACRheum
#lupus #MedSky #ClinicalTrial #SLE #pharmacology #FDA
via ACRheum
#lupus #MedSky #ClinicalTrial #SLE #pharmacology #FDA